Background: The aim of this investigator-initiated trial is to evaluate the safety and efficacy of the novel Luminor® paclitaxel-coated drug-eluting balloon (DEB) catheter (iVascular, S.L.U., Barcelona, Spain) in inhibiting restenosis and in ensuring long-term vascular patency.
Background
The Luminor® paclitaxel-coated drug-eluting balloon (DEB) catheter (iVascular, S.L.U., Barcelona, Spain) is specially designed for the percutaneous transluminal angioplasty (PTA) technique. The DEB catheter is based on a proprietary Transfertech® coating technology. This has been engineered to improve clinical efficacy by optimizing coating properties and device functionalities. It allows a homogeneous and precise paclitaxel concentration of 3 μg/mm 2 on the PTA balloon surface. This patientblinded randomized controlled trial (RCT) focuses on the efficacy and the clinical outcome of the Luminor® paclitaxel-coated DEB catheter.
Experience in animal models has shown that paclitaxelcoated DEB catheters demonstrate an inhibition of neointimal hyperplasia after PTA [1] . The safety issue of paclitaxel-coated DEB catheters has been well-investigated in clinical studies for the use in femoropopliteal arteries using paclitaxel-coated DEB catheters from other manufacturers, with drug concentrations ranging from 2.0 to 3.5 μg/mm 2 on the PTA balloon surface [2] . The THUNDER and FemPac RCTs used the iopromide-matrixcoated Paccocath® catheter with comparable study designs.
The results of both trials demonstrated that the paclitaxelcoated DEB catheter offered superior restenosis inhibition and reduced target lesion revascularization (TLR) rates in the femoropopliteal artery [3, 4] . These results were confirmed with IN.PACT Pacific® urea-matrix-paclitaxel-coated DEB catheters in the same target vessel [5] .
The EffPac study design follows the Trans-Atlantic InterSociety Consensus -II (TASC II), which provides comprehensive, evidence-based recommendations for vascular practice and treatment decisions between endovascular and surgical techniques. According to the TASC II on femoropopliteal lesions, endovascular therapy is the treatment of choice for type A lesions (single occlusion ≤5 cm) and is the preferred treatment for type B lesions (occlusions ≤15 cm) (Recommendation No. 37) [6] . The EffPac trial will include both TASC II type A and type B lesions.
Study hypothesis
That Luminor® paclitaxel-coated balloon catheters will be associated with significantly lower reocclusion and restenosis rates as compared to noncoated, plain old balloon angioplasty (POBA) catheters in both TASC II type A and type B lesions (≤15 cm) of the superficial femoral artery (SFA) and the proximal popliteal artery (PA).
Methods

Study design
EffPac is designed as a randomized controlled, multicenter trial in which the Luminor® paclitaxel DEB catheter is compared to the POBA catheter in de novo stenotic/restenotic or occlusive lesions in the SFA and/or proximal PA to prevent vessel restenosis or reocclusion (Fig. 1) . The clinical endpoints used for classification focus primarily on effectiveness, followed by safety monitoring and side effects.
Study setting
The University Hospital Jena, as the coordinating study center, is an academic hospital with intense research activity. The other 10 study sites are located on German national territory. The detailed list of study sites can be accessed at (NCT02540018).
Primary endpoint
The primary endpoint of EffPac trial is the late lumen loss (LLL), defined angiographically as the difference between the intraluminal vessel diameter (in mm) at 6 months follow-up (FU) and the diameter measured immediately post procedure.
Secondary endpoints
Occurrence of restenosis at follow-up (FU) (defined as incidence of stenosis ≥50 %) (6 months and 12 months) Freedom from target lesion revascularization (TLR) at FU (6 months and 12 months) Freedom from target vessel revascularization (TVR) at FU (6 months and 12 months) Change of Rutherford stage at baseline and at FU: (0) asymptomatic, (1) mild claudication, (2) moderate claudication, (3) severe claudication, (4) ischemic rest pain, (5) minor tissue loss, (6) ulceration or gangrene Change of ankle-brachial Index (ABI) from baseline at FU (6 months and 12 months) Change in quality of life according to the WIQ and the EuroQoL 5 dimensions questionnaire (EQ-5D) from baseline at FU (6 months and 12 months) Major and minor amputation rate at the index limb Number of dropouts All-cause mortality Definitions LLL as the primary efficacy endpoint was not designated as a safety issue, and allows researchers to evaluate the efficacy of paclitaxel-coated DEB angioplasty as a drug device in inhibiting restenosis and reocclusion of target lesions in the SFA. LLL is defined as the angiographic minimum lumen diameter (MLD) immediately after PTA minus the MLD at angiographic follow-up (Fig. 2) . The LLL represents a measure that corresponds to neointimal growth inhibition and it predicts TLR occurrence [7] . TLR is defined as a clinically driven repeated percutaneous intervention of the target lesion or bypass surgery of the target vessel.
Patients
A total of 172 patients (reflecting a 10 % loss to follow-up) with stenosis or occlusion of the SFA and PA, to be randomly assigned to study groups.
Eligibility criteria
Ages eligible for study: 18 years and older. Genders eligible for study: both. Acceptance of healthy volunteers: no.
Inclusion criteria
The subject must meet all of the following general inclusion criteria:
1. Age ≥18 years 2. Subject must agree to undergo the 6-month angiographic FU as well as the clinical FU (at 6-and 12-months post procedure) 3. Peripheral vascular disease Rutherford classes 2-4 4. De novo stenotic/restenotic lesion or occlusive lesions in the SFA and/or proximal PA 
5.
If the index lesion is restenotic, the prior PTA must have been more than 30 days prior to treatment in the current study 6. At least 70 % diameter stenosis or occlusion 7. Target lesion length: ≤15 cm (TASC II types A and B) 8. Only one lesion per limb and per patient can be treated 9. At least one patent infrapopliteal run-off artery to the foot of the index limb 10.Successful endoluminal guidewire passage through the target lesion 11.Predilatation prior to randomization 12.Life expectancy, in the investigators' opinion, of at least 1 year 13.Subject is able to verbally acknowledge and understand the aim of this trial and is willing and able to provide informed consent
Exclusion criteria
The subject must not meet any of the following general exclusion criteria: in another interventional study 18.Treatment of in-stent restenosis of target lesion is not allowed, but treatment of in-stent restenosis outside of target lesion in the target vessel is not an exclusion criterion
Recruitment
All compliant patients undergoing angioplasty to the SFA and PA are accurately informed about the trial in a prescreening phase. The study nurse visits the eligible patient on the ward or at the outpatient clinic and explains to them the objectives and procedures that are relevant to the study and hands them information material such as the study flyer. If the patient gives consent to participate in the EffPac trial, the investigator is responsible for obtaining written informed consent from the patient after adequate explanation of all aspects of the trial that are relevant for the patients' decision to participate. Before participation in the study, the investigator must also inform the patients that they are completely free to refuse to enter the study or to withdraw from it at any time and for any reason. The patient is enrolled in the study after it has been determined that they meet all the inclusion criteria and none of the exclusion criteria. The investigator enrolls the patients and assigns the participants to intervention.
Safety and quality control
A Data and Safety Monitoring Board (DSMB) is established in order to protect the safety, rights and wellbeing of study participants. The DSMB consists of a group of two independent physicians and a statistician with pertinent expertise who review and adjudicate important endpoints and relevant adverse events reported by the study investigators. The DSMB members serve as an advisory panel to the study investigators.
Compensation for post-trial care, for those patients who suffered harm from trial participation, is covered by a trial health insurance.
Confidentiality
The investigators and the study staff will keep all information provided by the sponsor and about the study patients in strict confidence. For protection of these data, organizational procedures are implemented to prevent their distribution to unauthorized persons. Appropriate local data legislation will be fulfilled in its entirety.
Financial disclosure
All investigators must sign the study protocol acceptance and the financial disclosure form.
Medications
Patients will receive dual antiplatelet therapy (DAPT) during a period of at least 4-6 weeks after angioplasty, if tolerated. The typical, recommended DAPT regimen consists of acetylsalicylic acid (ASA) (minimum 75 mg/day) and a P2Y12 inhibitor, e.g., clopidogrel (minimum 75 mg/day). Alternate DAPT regimens may be followed if justified by individual patient requirements, e.g., if there is documented intolerance to any of these drugs, or the patient is already taking a different antiplatelet therapy (with at least two approved drugs) due to comorbid conditions. The investigator will be guided by the drug manufacturer's instructions, available scientific evidence and medical guidelines applicable to patients with peripheral arterial disease.
After 4-6 weeks of DAPT post procedure, patients will receive at least one antiplatelet drug indefinitely. Patients receiving anticoagulant therapy should not receive additional antiplatelet drugs if, in the opinion of the investigator, this could present an intolerable bleeding risk.
Patients who do not take already DAPT drugs at admission should receive an appropriate periprocedural loading doses. Recommended minimum loading doses are 300 mg for ASA and 300 mg for clopidogrel. At least one antiplatelet drug is administered prior to the angioplasty, and the second antiplatelet drug should be administered within 2 h post procedure if not given beforehand. At the time of the procedure, patients should receive an intra-arterial bolus of heparin (usually 5000 IU), or alternate anticoagulants as substitutes for heparin if justified by individual patient requirements. The typical, recommended DAPT and anticoagulation regimen must be consistently followed for both study and control devices.
Adverse and serious events
An adverse event (AE) is any untoward medical occurrence in a subject that occurs in conjunction with the use of the study device, whether or not the event is considered device-related.
New and worsening signs and symptoms of underlying or emerging disease must be recorded as adverse events.
Adverse events may include, but are not limited to:
Subjective or objective symptoms spontaneously reported by the patient or subject and/or observed by the investigator or medical staff Laboratory, electrocardiogram (ECG) or physical examination abnormalities of clinical significance or for which a medical intervention was initiated A serious adverse event (SAE) or serious adverse device effect (SADE) is defined as an AE or adverse device effect (ADE) that results in any of the following outcomes:
Death, A life-threatening adverse event, Inpatient hospitalization or prolongation of existing hospitalization, A persistent or significant disability/incapacity A congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a SAE when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above.
All AEs during the safety observation period, whether considered associated with the use of the study endovascular device or not, must be monitored until symptoms subside or return to baseline, or until there is a satisfactory explanation for the changes observed. Follow-up information will be submitted to the study sponsor as it becomes available.
The safety observation period starts with successful randomization and ends at the 12-month follow-up (visit 3).
Statistical analysis
All analyses of primary and secondary endpoints follow the intention-to-treat (ITT) principle and are performed for all participants based on the group to which they were randomly allocated. Multiple imputation of missing values will be conducted for the primary endpoint to evaluate the robustness of the conclusions.
Sample size
The primary objective of the trial is to show that LLL in the paclitaxel-coated DEB catheter group is less than that in the POBA catheter group.
In a pilot trial by Werk et al. [3] , average lumen loss after 6 months was 0.5 mm (SD = 1.1 mm) in the coated balloon group and 1.0 mm (SD = 1.1 mm) in the uncoated balloon group. At a 5 % significance level, a two-sided independent samples t test will have an 80 % power to detect an effect size of 0.45 when the sample size in each group is 77 (nQuery Advisor 7.0). Taking into account a dropout rate for primary endpoint data of 10 %, a total of 172 patients should be randomized.
Data analysis plan
The primary endpoint will be analyzed by a linear mixed model with fixed effect of the treatment and random center effects.
Kaplan-Meier curves will be estimated for the secondary endpoints of mortality and minor and major amputations. The survival curves of the treatment groups are compared using the log-rank test.
For Rutherford stage, the change in class number between baseline and follow-up will be calculated for each patient. To compare both treatment groups regarding the change, Cochran-Mantel-Haenszel statistics will be applied.
Change of ABI and "Quality of Life" according to the EQ-5D and the WIQ will be compared between the treatment groups by an independent sample t test or a nonparametric Mann-Whitney U test according to the data distribution. Frequency of restenosis, number of dropouts, TLR and TVR will be compared by Fisher's exact test between groups.
Study schedule Visit 0: (baseline period/screening)
The screening process will be used to determine the inclusion or exclusion of a patient in the study. After the patient has signed the informed consent form, the screening process may begin.
This process includes the investigator's assessment of the patient's medical records and diagnosis, including:
Demographic data: gender, date of birth, height, weight, smoking status Medical history: (including concomitant diseases (hypertension, hyperlipidemia, diabetes mellitus, renal insufficiency, angina pectoris, arrhythmia, stroke, congestive heart failure, coronary arterial disease, transient ischemic attack, myocardial infarction) Concomitant medication and medical treatments Anticoagulants Physical assessment Routine laboratory tests (with pregnancy test in women with childbearing potential) Duplex ultrasound (DUS) of the pelvic and lower-limb arteries -optional (according to the physician's decision) EQ-5D and Walking Impairment Questionnaire (WIQ) Ankle-brachial Index (ABI) Rutherford stage assessment
Visit 1: treatment (angioplasty)
The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. All sites will have access to an emergency unit to enable interventions to be converted to bypass surgery, e.g., in case of failed PTA. The patient is positioned on the angiographic table and draped in a sterile fashion. The standard vascular access accords with the ipsilateral or contralateral femoral artery in relation to the target vessel. The endovascular procedure can be performed in a direct antegrade or a crossover retrograde technique.
An introducer sheath will be inserted over a guidewire. Five thousand I.U. heparin is injected intra-arterially (i.a.) to prevent periprocedural thrombotic events. Alternative periprocedural anticoagulation regimens may be applied if justified by individual patient requirements. Endoluminal guidewire passage through the stenotic and occlusive femoropopliteal lesion is mandatory for study inclusion.
A POBA PTA balloon of appropriate balloon diameter and length and catheter working length is selected according to the characteristics of the target vessel and the lesion for predilatation and assessment by angiography (digital subtraction angiography (DSA) or X-ray angiography (XA)). A ruler must be placed adjacent to the target vessel for accurate measuring.
Predilatation in both study arms with POBA catheters:
Inflation time minimum 30 s (without limit above) PTA balloon inflation up to nominal pressure Diameter of POBA catheter according to reference measurement directly proximal to the lesion Length of POBA catheter with 10 mm overlap proximal and distal to the lesion Repeated predilatations (up to three) with the same POBA catheter is allowed in case of PTA-resistant stenosis
After predilatation of the target lesion, an angiographic assessment will be performed (DSA or XA). Again, a ruler must be placed adjacent to the target vessel for accurate measuring. The treatment group represents the Luminor® DEB catheter and the control group the POBA catheter using a CE-marked non-drug-eluting PTA balloon catheter.
Randomization occurs only after the target lesion has been successfully crossed by a guidewire and there is fulfillment of angiographic inclusion/exclusion criteria. Randomization will be performed by sealed envelope pull. Due to the nature of the study, the investigator will not be blinded to the treatment allocation. The allocation is patient-blinded. Unblinding is only permissible if knowledge of the study treatment is absolutely essential for further management of the patient.
For both Luminor 35® paclitaxel-coated DEB angioplasty (experimental group) and the POBA catheter (control group), identical procedures for both study arms will be adopted:
Inflation time 60 ± 10 s PTA balloon inflation up to nominal pressure Diameter of PTA balloon catheter should be sized ≥1:1 according to reference vessel diameter measurement directly proximal to the lesion Length of PTA catheter with 10 mm overlap proximal and distal to the lesion The longest possible adaptable balloon must be used for the lesion. If this is not applicable, overlapping is allowed In case two or multiple DEB catheters are used a minimal overlap of 5 to 10 mm is required After dilatation of the target lesion, the PTA catheter is withdrawn through the introducer sheath and a post-PTA angiogram is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiogram (DSA or XA) of the BTK (below the knee) arteries is required.
In case of a nonflow-limiting or flow-limiting dissection, a prolonged PTA with the same PTA balloon is required. If the flow-limiting dissection persists, the required dropout stenting is not an exclusion criterion (Fig. 3) .
If stenting is necessary, stent grafts (covered stents) or drug-coated stents (heparin, paclitaxel, etc.) cannot be used. The 12-month follow-up is an in-person visit and the following data will be collected:
DUS to identify the occurrence of restenosis Medication TLR/TVR ABI Rutherford stages WIQ, EQ-5D AEs/SAEs
To promote follow-up completion, the study nurse is in continuous contact with the study patients and in timely fashion sends letters to invite patients to the follow-up visits.
A schedule of enrollment, interventions and assessments for the EffPac trial following Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) is summarized in Table 1 . 
Monitoring and reporting
The sponsor or the appointed Clinical Research Organization (CRO) is responsible for the monitoring activities. The site initiation, monitoring and close-out visits in general will be performed on site. The purpose of the monitoring is primarily to ensure the protection of the rights and safety of the participating subjects. After the monitoring visits a detailed report will be created. Protocol deviations that occur, such as AEs and SAEs, are discussed with the investigator and reported to the sponsor within 24 h. Furthermore, the monitoring is to ensure good data quality and a continuing conduction of the clinical trial in accordance with the CIP, ISO 14155, the ICH-GCP and the Declaration of Helsinki.
Data collection
For each randomized patient an electronic Case Report Form (CRF) will be completed. Data capture takes place ABI Ankle-brachial Index, AE adverse events, DEB drug-eluting balloon, DSA digital subtraction angiography, LLL late lumen loss, POBA plain old angioplasty balloon, QoL quality of life, SAE serious adverse events, TLR target lesion revascularization, TVR target vessel revascularization, US ultrasound, WIQ Walking Impairment Test, XA X-ray angiography via web application on the servers of the Center for Clinical Studies at Jena University Hospital with "OpenClinica®", a study management software. OpenClinica® meets all regulatory requirements (GCP, 21CFR Part 11).
Patient files and other source data (particularly with regard to informed consent, date of X-rays and outcome) must be kept for the maximum period of time permitted by the hospital or institution, but at least 30 years. The sponsor of the trial must keep all other documentation pertaining to the trial for at least 15 years.
Auditing
All local and national regulations are observed. This includes an audit by the sponsor's representatives during the course of the study. All protocol modifications were communicated to the relevant parties.
Amendment
In February 2016 an amendment was implemented after notification and approval by the regulatory authorities. 
Trial status
Sponsor
Universitätsklinikum Jena, Bachstrasse 18, 07745 Jena, Germany.
Discussion
Multiple randomized "first-in-man" trials and registries [3, 4, 8, 9] of first-generation drug-coated balloon technology have convincingly demonstrated the superiority of paclitaxel-coated DEB angioplasty compared to POBA in relation to LLL, restenosis rate and freedom from TLR. In line, a meta-analysis including 381 patients overall (DEB angioplasty N = 186 versus POBA N = 195) confirmed angiographically the superiority of paclitaxel-coated DEB angioplasty in reducing significantly the TLR rate (12.2 % versus 27.7 %, respectively) and the restenosis rate (18.7 % versus 45.5 %, respectively) compared to POBA [10] . Interestingly, up to now only drugeluting devices for peripheral interventions based on paclitaxel-coated technology have demonstrated clinical benefit. There are nine RCTs comparing paclitaxel-coated DEB angioplasty versus POBA, five of them industrysponsored. A total of 1448 patients were recruited (range, 50 to 479). The most common primary endpoint is "late lumen loss" (LLL) at 6 months. Seven out of nine RCTs were core-laboratory adjudicated for primary outcome assessment (Table 2) [3-5, 8, 11-17] . First, paclitaxel (3 μg/m 2 ) was combined with iopromide as an excipient (Paccocath) [3, 4] followed by others such as polysorbate and sorbitol (Lutonix 35, LEVANT I) [8] or urea (IN.PACT Pacific, Pacifier®) [5] and butyryl-trihexyl citrate carrier substances (Passeo Lux, Biolux P-1) [11] .
After having demonstrated the proof of concept, two RCTs followed: the IN.PACT SFA trial [12] , using the IN.PACT Admiral® (Medtronic, Santa Rosa, CA, USA) balloon catheter (urea and 3.5 μg/m 2 paclitaxel) and enrolling 331 patients revealed at 12 months a significantly lower clinically driven TLR rate for DEB angioplasty compared to uncoated POBA (2.4 % versus 20.6 %; p < 0.001) and a higher primary patency rate of 82.2 % for DEB angioplasty versus 52.4 % for POBA; the second trial (LEVANT II) [16] included 476 patients overall who were treated with the Lutonix® (Bard, Covington, GA, USA) paclitaxel-coated DEB angioplasty (polysorbate/ sorbitol and 2 μg/m 2 paclitaxel). The primary patency at 12 months was favorable for paclitaxel-coated DEB angioplasty (65.2 % versus 52.6 %; p = 0.02) and again [18] . In this prospective, multicenter, single-arm study 58 femoropopliteal artery lesions in 50 patients were treated and the preliminary data revealed a primary patency rate of 80.3 % and freedom from clinically driven TLR of 85.8 % with no deaths or amputations at 24 months. Data from alreadyinitiated, randomized multicenter trials comparing Stellarex® paclitaxel-coated DEB angioplasty versus POBA are, however, still ongoing.
As uncompromised drug delivery to the target lesion in the vasculature is a major issue, strong efforts were made to address this goal. For example, Boston Scientific (Marlborough, MA, USA) has investigated the Ranger® paclitaxel-coated DEB catheter. This device has a proprietary trans-Pax coating® technology designed to maintain drug-coating integrity and maximize drug transfer efficiency. All the different paclitaxel-coated DEB catheters available until now have in common that their proprietary coating technology enables consistent and predictable drug delivery to the vessel wall.
As mentioned above, the investigators of this trial evaluated the concept of homogenous distribution of paclitaxel 3 μg/cm 2 on the balloon's surface by applying a proprietary Transfertech® coating technology. The drug is deposited on the balloon's surface by means of ultrasonographic exposure to guarantee a uniform diameter in nanodrops to finally constitute an ultrathin multilayer coating. This technology has been engineered to improve clinical efficacy by optimizing coating properties and device functionalities. In animal models, this concept showed convincing results and promising first in-men studies resulted in the CE mark being granted for the Luminor® DEB catheter.
Overall, paclitaxel-coated DEB angioplasty is an innovative technology that offers multiple advantages and follows a "leaving-nothing-behind" concept that maintains all future options open for further treatment. This possibility fits well, as the natural course of peripheral arterial disease is, unfortunately, progressive. 
